GlaxoSmithKline PLC's leading sales in the US OTC smoking cessation category could grow with its proposal for the first mouth spray product to be available Rx or nonprescription in the country.
The Food and Drug Administration has scheduled a Nonprescription Drugs Advisory Committee meeting for 18 September to consider GlaxoSmithKline Consumer Healthcare Holdings LLC's new drug application for an OTC nicotine...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?